Frazier Life Sciences Management
BCYC icon

Frazier Life Sciences Management’s Bicycle Therapeutics BCYC Stock Holding History

Frazier Life Sciences Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-603,521
Closed -$26.5M – 43
2022
Q1 		$26.5M Buy
+603,521
New +$28.2M 2.26% 14

Other funds holding BCYC

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Tybourne Capital Management
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Samlyn Capital
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
SV Health Investors
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Frazier Life Sciences Management's BCYC Position: Q2 2022 in Review

Frazier Life Sciences Management sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 603,521 shares — an estimated $26.5M sold.

Frazier Life Sciences Management first reported a position in BCYC in Q1 2022 and held it in 1 quarter. The position peaked at $26.5M in Q1 2022. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

  • Frazier Life Sciences Management reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Frazier Life Sciences Management sold 603,521 Bicycle Therapeutics shares in Q2 2022, an estimated $26.5M.
  • Frazier Life Sciences Management first reported a position in Bicycle Therapeutics in Q1 2022 and held it in 1 quarter.
  • Frazier Life Sciences Management's Bicycle Therapeutics position peaked at $26.5M in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Frazier Life Sciences Management's 13F filing for Q2 2022, filed 10 Aug 2022.